SANUWAVE Health, Inc. Provides Revenue Guidance for the First Quarter and Full Year of Fiscal Year Ending December 31, 2024
March 22, 2024 at 06:00 am EDT
Share
SANUWAVE Health, Inc. provided revenue guidance for the first quarter and full year of fiscal year ending December 31, 2024. The company forecasts first quarter 2024 revenue to rise 45% to 55% vs first quarter 2023 and for gross margin as a percentage of revenue to increase back into the mid 70s.
For the full year, the company anticipates revenue growth of over 50% compared to fiscal year 2023 with fiscal year 2024 revenues expected to total over $30 million.
Sanuwave Health, Inc. is an ultrasound and shock wave technology company. The Company is a provider of Food and Drug Administration (FDA)-approved wound care products. It is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. The Company applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and others. Its two primary systems are UltraMIST and PACE. The UltraMIST system provides, through a fluid mist, low-frequency, non-contact, and pain free ultrasound energy deep inside the wound bed that promotes healing from within. The PACE systems use acoustic pressure shockwaves generated by the Company's Pulsed Acoustic Cellular Expression (PACE) technology to converge at precise selected targets to produce an extremely short duration compression burst.
SANUWAVE HEALTH, INC. 
